Tags : Jardiance

Eli Lilly Reports Results of Jardiance (empagliflozin) in P-III EMPEROR

Shots: The P-III EMPEROR Trial involves assessing of Jardiance (10 mg) vs PBO in two studies EMPEROR-Reduced [NCT03057977, N=3,730] & EMPEROR-Preserved [NCT03057951, N=5,990] in patients with HFrEF & HFpEF respectively The EMPEROR-Reduced study meets its 1EPs in reducing the risk for the composite of cardiovascular death or hospitalization due to heart failure while the overall […]Read More

Boehringer Ingelheim and Lilly Commence P-III EMPULSE Study to Evaluate

Shots: The P-III EMPLULSE study (NCT04157751) will evaluate clinical benefits safety and tolerability of Jardiance (empagliflozin, 10mg, PO) in ~500 patients hospitalized for acute heart failure who have been stabilized including patients both with and without T2D The P-III EMPULSE study will evaluate whether Jardiance will able alleviate symptoms associated with HF and improve outcomes […]Read More

Boehringer Ingelheim and Lilly Restructure their Alliance to Emphasis Full

Shots: The global companies modernize their alliance as of Jan 01, 2020 to completely focus their expertise and investment on the development and commercialization of Jardiance (empagliflozin) for T2D, HF and CKD   As per the amended agreement, the companies will revise the margin sharing structure for ongoing payments from Jan 01, 2020. Trajenta (linagliptin) […]Read More

Boehringer Ingelheim (BI) & Eli Lilly Reports RWE Results of

Shots:   The EMPRISE study involves assessing of Jardiance vs DPP-4 inhibitors in ~35,000 people with T2D initiated from 2014 to 2019, demonstrated 44% reduction in relative risk of hospitalization for HHF and was consistent in patients with or without CV diseases The above results support finding from EMPA-REG OUTCOME trial assessing jardiance (10/25 mg […]Read More